Key Highlights

  • Revenue rose 24% to £47.5m for the year to 31 January 2026
  • SLE neonatal ventilation product sales surged 56% to £31.6m
  • Adjusted EBITDA rose to £2.8m from £0.2m; statutory pre-tax loss narrowed to £1.0m from £15.7m
  • Net Debt cut 39% to £5.1m on Operating Cash Flow of £7.5m
  • Agreed to transfer its Micrel infusion distribution back to Micrel Medical Devices, sharpening focus on neonatal care
  • Secured a £9.5m export contract and a multi-year US purchasing agreement for its Airon division

After a bruising couple of years, Inspiration Healthcare (LSE:IHC) has staged a convincing recovery. The AIM-listed specialist in neonatal intensive-care technology reported full-year results for the 12 months to 31 January 2026 that showed strong Revenue growth, a sharp improvement in profitability and a materially healthier balance sheet. Chief executive Raffi Stepanian called it "a transformational year," marking the group's shift "from stabilisation to growth execution". With a strategic divestment sharpening the focus on neonatal care, the Investment story has moved from repair to expansion.

What Has Happened?

Inspiration Healthcare's headline achievement was a 24% rise in revenue to £47.5m, up from £38.3m, driven above all by its SLE neonatal ventilation products. The company also announced a strategic simplification: it agreed to transfer distribution of its Micrel infusion products back to Micrel Medical Devices SA, effective at the end of the 2027 financial year, allowing management to concentrate resources on its core neonatal franchise. That divestment is expected to reduce net debt by roughly a further 20% in FY27.

The year also featured commercial wins that underpinned the growth, including a £9.5m export contract and a multi-year purchasing agreement for the group's Airon division with a major US healthcare provider — evidence of the international expansion at the heart of the strategy. Results were published on 16 June 2026.

The Numbers Investors Need to Know

Beyond the 24% top-line rise, the standout figure was SLE, whose product sales surged 56% to £31.6m from £20.2m, making it the clear engine of growth. Gross Margin improved to 43.7% from 42.8%, and adjusted EBITDA leapt to £2.8m from just £0.2m the prior year. Adjusted operating profit swung to £0.8m from a £1.9m loss.

At the statutory level the group narrowed its pre-tax loss dramatically to £1.0m from £15.7m — the prior year having been weighed down by heavy impairments — with basic loss per share improving to 1.16p from 18.82p. Cash generation was a highlight: operating cash flow of £7.5m, against a £1.5m outflow a year earlier, helped cut net debt by 39% to £5.1m from £8.3m. The board declared no dividend, maintaining its suspension. Management said current trading is in line with expectations for FY27, supported by a growing order book and improving pipeline.

Why This Matters

These results validate a turnaround that had been in doubt. The move from a small EBITDA figure to £2.8m, combined with a £9m swing in operating cash flow, shows a Business that has regained financial control. The 39% cut in net debt removes a significant overhang and gives management room to invest.

Strategically, the divestment of infusion is the clearest signal yet of intent. By exiting a non-core distribution activity and doubling down on neonatal ventilation — where SLE is a recognised specialist and Demand is growing internationally — Inspiration is positioning itself as a focused, higher-margin MedTech play. For investors, that focus reduces complexity and concentrates the investment story on a defensible clinical niche: technology that supports the survival of premature and critically ill newborns.

What Is Driving the Story?

The primary driver is SLE, whose 56% sales growth reflects both new product traction and international demand for neonatal ventilators. Export success — including the £9.5m contract and the Airon agreement in the United States — shows the group broadening its geographic base beyond the UK. Neonatal intensive care is a structurally growing market, underpinned by clinical need and long replacement cycles for Capital equipment.

The second driver is operational discipline. Improved gross margin, tight cost control and strong cash conversion turned modest revenue growth into a disproportionate improvement in EBITDA and net debt. The third is strategic clarity: divesting infusion frees management bandwidth and capital to pursue the neonatal opportunity, while further de-gearing the balance sheet.

What Could Drive the Shares Next?

The most immediate catalyst is continued momentum in the order book and pipeline that management has flagged for FY27. Confirmation that SLE growth is sustaining, and that international contracts are converting into recurring revenue, would reinforce the recovery narrative. Completion of the infusion divestment and the associated ~20% net-debt reduction would further strengthen the Balance Sheet and could open the door to renewed investment or, in time, the resumption of dividends.

Progress in the United States — building on the Airon agreement — is a particularly important lever, given the scale of that market. Additional large export contracts, new product launches in neonatal care, and further margin gains would all support the shares. Evidence that the group can convert its stronger cash generation into durable, profitable growth is the key test.

Risks Investors Should Watch

Concentration is the most obvious risk: with SLE now driving the bulk of growth, any slowdown in that range or in neonatal capital spending by hospitals would weigh heavily. Large export and tender contracts can be lumpy, making revenue less predictable from period to period.

The group still carries £5.1m of net debt and pays no dividend, so financial flexibility, while much improved, remains constrained. Execution risk attaches to the infusion divestment and to the ambition of expanding in competitive international markets, including the US, where larger rivals operate. Currency movements, procurement cycles in publicly funded health systems, and regulatory requirements for medical devices add further layers of risk. The turnaround is real, but growth must now be proven durable.

The Bottom Line

Inspiration Healthcare's FY26 results mark a genuine inflection: 24% revenue growth, a near-fourteenfold rise in adjusted EBITDA, strong cash generation and a 39% cut in net debt add up to a business that has decisively moved past its troubles. The 56% surge in SLE sales and the decision to divest infusion show a company concentrating on what it does best — neonatal ventilation for the most vulnerable patients. The next phase is about sustaining international growth and converting momentum into consistent profit. If management delivers, the recovery could mature into a compelling growth story.